Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Jacques Body

Showing results (31-40 of 133) with videos related to

Pageof 14
Sort By:
Expert Opinion on Drug Safety|May 9, 2008
Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone healthFabrice Journé, Jean-Jacques Body, Guy Leclercq, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Sowing the soil for cure? Results of the ABCSG-12 trial open a new chapter in the evolving adjuvant bisphosphonate story in early breast cancerPhilippe L Bedard, Jean-Jacques Body, Martine J Piccart-Gebhart
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 8, 2013
Reducing the burden of bone metastases: current concepts and treatment optionsRoger von Moos, Cora Sternberg, Jean-Jacques Body, et al.
BMC Urology|September 22, 2018
Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completionJean-Jacques Body, Roger von Moos, Daniela Niepel, et al.
Calcified Tissue International|September 13, 2011
Hypophosphatemia related to paraneoplastic Cushing syndrome in prostate cancer: cure after bilateral adrenalectomyIsolde Ramon, Pierre Kleynen, Joseph Valsamis, et al.
Molecular and Cellular Endocrinology|October 27, 2004
Ligand-independent and agonist-mediated degradation of estrogen receptor-alpha in breast carcinoma cells: evidence for distinct degradative pathwaysDenis Nonclercq, Fabrice Journé, Jean-Jacques Body, et al.
Breast Cancer Research and Treatment|June 26, 2004
Estrogen responsiveness of IBEP-2, a new human cell line derived from breast carcinomaFabrice Journé, Jean-Jacques Body, Guy Leclercq, et al.
Journal of Medical Economics|February 22, 2013
The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in BelgiumJean-Jacques Body, Pierre Chevalier, Oliver Gunther, et al.
Cancer Treatment Reviews|May 20, 2008
Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategiesRobert E Coleman, Jean-Jacques Body, Julie R Gralow, et al.
Clinical Drug Investigation|December 14, 2006
Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trialMartin Pecherstorfer, Saul Rivkin, Jean-Jacques Body, et al.
Pageof 14

Showing results (31-40 of 133) with videos related to

Sort By:
Pageof 14
Expert Opinion on Drug Safety|May 9, 2008
Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone healthFabrice Journé, Jean-Jacques Body, Guy Leclercq, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Sowing the soil for cure? Results of the ABCSG-12 trial open a new chapter in the evolving adjuvant bisphosphonate story in early breast cancerPhilippe L Bedard, Jean-Jacques Body, Martine J Piccart-Gebhart
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 8, 2013
Reducing the burden of bone metastases: current concepts and treatment optionsRoger von Moos, Cora Sternberg, Jean-Jacques Body, et al.
BMC Urology|September 22, 2018
Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completionJean-Jacques Body, Roger von Moos, Daniela Niepel, et al.
Calcified Tissue International|September 13, 2011
Hypophosphatemia related to paraneoplastic Cushing syndrome in prostate cancer: cure after bilateral adrenalectomyIsolde Ramon, Pierre Kleynen, Joseph Valsamis, et al.
Molecular and Cellular Endocrinology|October 27, 2004
Ligand-independent and agonist-mediated degradation of estrogen receptor-alpha in breast carcinoma cells: evidence for distinct degradative pathwaysDenis Nonclercq, Fabrice Journé, Jean-Jacques Body, et al.
Breast Cancer Research and Treatment|June 26, 2004
Estrogen responsiveness of IBEP-2, a new human cell line derived from breast carcinomaFabrice Journé, Jean-Jacques Body, Guy Leclercq, et al.
Journal of Medical Economics|February 22, 2013
The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in BelgiumJean-Jacques Body, Pierre Chevalier, Oliver Gunther, et al.
Cancer Treatment Reviews|May 20, 2008
Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategiesRobert E Coleman, Jean-Jacques Body, Julie R Gralow, et al.
Clinical Drug Investigation|December 14, 2006
Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trialMartin Pecherstorfer, Saul Rivkin, Jean-Jacques Body, et al.
Pageof 14